These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22059392)

  • 1. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
    Miehlke S; Krasz S; Schneider-Brachert W; Kuhlisch E; Berning M; Madisch A; Laass MW; Neumeyer M; Jebens C; Zekorn C; Knoth H; Vieth M; Stolte M; Lehn N; Morgner A
    Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
    Sacco F; Spezzaferro M; Amitrano M; Grossi L; Manzoli L; Marzio L
    Dig Liver Dis; 2010 Feb; 42(2):110-4. PubMed ID: 19846355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Haferland C; Bästlein E; Jebens C; Zekorn C; Knoth H; Stolte M; Lehn N
    Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
    BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
    Kiliç ZM; Köksal AS; Cakal B; Nadir I; Ozin YO; Kuran S; Sahin B
    Dig Dis Sci; 2008 Dec; 53(12):3133-7. PubMed ID: 18465244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H; Kim N; Lee BH; Hwang TJ; Lee DH; Park YS; Nam RH; Jung HC; Song IS
    Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM; Kim N; Lee DH; Park YS; Kim YR; Kim JS; Jung HC; Song IS
    Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
    Nista EC; Candelli M; Zocco MA; Cazzato IA; Cremonini F; Ojetti V; Santoro M; Finizio R; Pignataro G; Cammarota G; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 May; 21(10):1241-7. PubMed ID: 15882245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J; Pevec B; Tomić M; Marusić M; Bakula V; Bago P
    Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.